Utilize este identificador para referenciar este registo: https://hdl.handle.net/10216/127044
Registo completo
Campo DCValorIdioma
dc.creatorGaspar, TB-
dc.creatorSá, A-
dc.creatorLopes, JM-
dc.creatorSobrinho-Simões, M-
dc.creatorSoares, P-
dc.creatorVinagre, J-
dc.date.accessioned2020-05-13T10:50:29Z-
dc.date.available2020-05-13T10:50:29Z-
dc.date.issued2018-
dc.identifier.issn2073-4425-
dc.identifier.urihttps://hdl.handle.net/10216/127044-
dc.description.abstractTumour cells can adopt telomere maintenance mechanisms (TMMs) to avoid telomere shortening, an inevitable process due to successive cell divisions. In most tumour cells, telomere length (TL) is maintained by reactivation of telomerase, while a small part acquires immortality through the telomerase-independent alternative lengthening of telomeres (ALT) mechanism. In the last years, a great amount of data was generated, and different TMMs were reported and explained in detail, benefiting from genome-scale studies of major importance. In this review, we address seven different TMMs in tumour cells: mutations of the TERT promoter (TERTp), amplification of the genes TERT and TERC, polymorphic variants of the TERT gene and of its promoter, rearrangements of the TERT gene, epigenetic changes, ALT, and non-defined TMM (NDTMM). We gathered information from over fifty thousand patients reported in 288 papers in the last years. This wide data collection enabled us to portray, by organ/system and histotypes, the prevalence of TERTp mutations, TERT and TERC amplifications, and ALT in human tumours. Based on this information, we discuss the putative future clinical impact of the aforementioned mechanisms on the malignant transformation process in different setups, and provide insights for screening, prognosis, and patient management stratification.-
dc.description.sponsorshipAcknowledgments: This work was supported by PhD grant from FCT—Fundação para a Ciência e a Tecnologia to T.B.G. (SFRH/BD/129431/2017). This work was also financed by FEDER—Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020—Operacional Programme for Competitiveness and Internationalization (POCI), Portugal 2020, and by Portuguese funds through FCT in the framework of the project “Institute for Research and Innovation in Health Sciences” (POCI-01-0145-FEDER-007274). Further funding was obtained from the project “Advancing cancer research: from basic knowledgment to application”; NORTE-01-0145-FEDER-000029; “Projetos Estruturados de I&D&I”, funded by Norte 2020—Programa Operacional Regional do Norte. Further funded by the European Regional Development Fund (ERDF) through the Operational Programme for Competitiveness and Internationalization—COMPETE2020, and Portuguese national funds via FCT, under project POCI-01-0145-FEDER-016390: CANCEL STEM”.-
dc.language.isoeng-
dc.publisherMDPI-
dc.relation.ispartofGenes, vol.9(5):241-
dc.rightsopenAccess-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.titleTelomere maintenance mechanisms in cancer-
dc.typeArtigo em Revista Científica Internacional-
dc.contributor.uportoInstituto de Investigação e Inovação em Saúde-
dc.identifier.doi10.3390/genes9050241-
dc.relation.publisherversionhttps://www.mdpi.com/2073-4425/9/5/241-
Aparece nas coleções:I3S - Artigo em Revista Científica Internacional

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
10.3390-genes9050241.pdf1.33 MBAdobe PDFThumbnail
Ver/Abrir


Este registo está protegido por Licença Creative Commons Creative Commons